Get the Stockscreener App
10.07
0.30%
0.03
After Hours:
10.07
Drugs Made In America Acquisition Corp Stock (DMAAU) Latest News
Initial Public Offering (IPO) News Live Feed - StockTitan
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation - Business Wire
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Our History - Baxter
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - Renaissance Capital
Drugs Made In America Acquisition Corp. (NASDAQ: DMAAU) Successfully Completes $200 Million IPOFort Lauderdale, FL, Jan. 29, 2025 – Drugs Made In America Acquisition Corp. (NASDAQ: DMAAU) recently announced the successful closure of its initial - Defense World
Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World
Allogene Therapeutics, Inc. Announces Departure of Timothy MooreOn January 23, 2025, Allogene Therapeutics, Inc. (NASDAQ: ALLO) revealed in an 8-K filing that Timothy Moore, the Company’s incumbent executive, would be concluding his tenure with the - Defense World
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals: MarketBeat News - Defense World
Frontier Group Holdings Makes Proposal to Spirit Airlines for Potential Business Combination - Defense World
Winmark Corporation (NASDAQ: WINA) Approves Quarterly Cash Dividend - Defense World
BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World
Medical Properties Trust Announces Commencement of Private Offering of Senior Secured Notes - Defense World
Juniper Networks Faces Legal Challenge with U.S. Department of Justice Seeking to Block Merger**On January 30, 2025, Juniper Networks, Inc. (NYSE: JNPR) encountered a significant hurdle as the U.S. Department of Justice filed a complaint in the Uni - Defense World
Boeing Reports Fourth Quarter ResultsARLINGTON, Va., January 28, 2025 – Boeing (NYSE: BA) has released its fourth quarter financial results for 2024, showcasing a revenue of $15.2 billion. The company reported a GAAP loss per share of ($5.46) and a c - Defense World
Adient Reports Financial Results for the Three Months Ended December 31, 2024Adient plc (NYSE: ADNT) recently released its condensed consolidated financial statements for the three months ending December 31, 2024. The company reported net sales of - Defense World
Hanover Bancorp, Inc. Announces Strong Fourth Quarter and Full Year 2024 Financial Results**WASHINGTON, D.C. – Hanover Bancorp, Inc. (NASDAQ: HNVR) reported its financial results for the fourth quarter and full year ended December 31, 2024, showc - Defense World
Barclays Lowers StoneCo (NASDAQ:STNE) Price Target to $10.00 - Defense World
Third Coast Bancshares (NASDAQ:TCBX) Stock Rating Lowered by Keefe, Bruyette & Woods - Defense World
SoFi Technologies (NASDAQ:SOFI) Price Target Raised to $20.00 - Defense World
SoFi Technologies (NASDAQ:SOFI) Price Target Raised to $14.00 - Defense World
Q1 Earnings Estimate for Hope Bancorp Issued By DA Davidson - Defense World
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering - The Manila Times
DMAAUDrugs Made In America Acquisition Corp. Units Latest Stock News & Market Updates - StockTitan
This New Pharma-Focused SPAC Just Raised $200MHere's What Makes It Unique - StockTitan
Drugs Made In America SPAC Nets $200M To Buy Pharma Biz - Law360
FG Merger II Corp. (FGMCU) Prices $80M IPO - SPACInsider
Drugs Made In America Acquisition Prices $200 Million IPO -January 28, 2025 at 04:53 am EST - Marketscreener.com
Drugs Made In America Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering - The Manila Times
New Pharma SPAC Launches With $200M War Chest: Inside The Latest Healthcare IPO - StockTitan
Danone’s yogurt sales surge among US consumers using GLP-1 drugs - Food Dive
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
The top 10 biopharma M&A deals of 2024 - FiercePharma
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn - Financial Times
Ozempic, Lego Bricks and Hearing Aids: What Trump’s Greenland Plan Could Hit - The New York Times
Trump’s Denmark Tariff Threat Means New Uncertainty for Ozempic Drugmaker Novo Nordisk - Barron's
2024 drug approvals: Small companies loom large with several key FDA nods - FiercePharma
Layoffs Continued Across Biopharma in 2024 - BioSpace
Bright Green enters into restructuring security agreement with Lynn Stockwell - Yahoo Finance
LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY - GlobeNewswire
Bright Green (BGXX) Announces Major Restructuring: Founder Returns as CEO, Plans API Manufacturing Focus - StockTitan
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval - Reuters
On an investment spree, Lilly will spend $3B to expand newly acquired injectables plant in Wisconsin - FiercePharma
7 Companies Owned by Pfizer - Investopedia
Recursion Completes Exscientia Merger, Creates AI Drug Discovery Powerhouse with $20B+ Pipeline - StockTitan
Vivek Ramaswamy's Net Worth: How Harvard-Yale graduate became rich by selling 'sick' pharma companies - The Economic Times
Inside CVS and Walgreens' downturn: How misguided M&A damaged America's drugstores - Fortune
Top 10 Asthma Drug Companies | Provides Best MedicinesMarket.us Media - Market.us Media - United States Market News
FTC’s watchdog role in pharma mergers: Road bumps and the way forward - Norton Rose Fulbright
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal - FiercePharma
IPO Roundup: Drugs Made in America Acquisition, FBS Global and more (NYSEARCA:IPO) - Seeking Alpha
BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda - FiercePharma
23andMe Is Sinking Fast. Can the Company Survive? - WIRED
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements - GlobeNewswire
WuXi Waylaid - The Wire
FTC v Actavis and pricing practices spearhead rise in US pharmaceutical antitrust cases - Global Competition Review
Understanding the debate over PBMs - Mercer
0.00%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):